72814-32-5 Usage
Description
BW 245C is a selective dopamine D2 receptor agonist, which plays a significant role in modulating the signaling pathways associated with neuronal injuries. It is a potent compound that has been widely studied for its potential therapeutic applications in the field of neuroscience.
Uses
Used in Pharmaceutical Industry:
BW 245C is used as a research compound for studying the effects of dopamine D2 receptor agonism on neuronal injuries. Its application in this field aids in understanding the underlying mechanisms of various neurological disorders and the potential development of novel therapeutic strategies.
Used in Neuroscience Research:
BW 245C is used as an experimental tool in neuroscience research to investigate the role of dopamine D2 receptors in primary cultured rat hippocampal neuron injuries. This helps researchers gain insights into the signaling pathways involved in neuronal damage and explore possible treatments for related conditions.
Used in Drug Development:
BW 245C serves as a lead compound in the development of new drugs targeting dopamine D2 receptors. Its agonistic properties make it a valuable asset in the search for more effective treatments for neurological disorders, such as Parkinson's disease, schizophrenia, and other conditions where dopamine receptor modulation is crucial.
Biological Activity
bw 245c is a kind of prostaglandin analogue with stable chemical properties which functions as a potent inhibitor of platelet aggregation. bw 245c could selectively active the dp1 receptor, and inhibit [3h]-pgd2 binding to isolated human platelet membranes, with the ki value of 0.9 nm [1].
in vitro
bw 245c could inhibit the aggregation of human and rat platelets induced by adp in a dose dependent manner, with the ic50 values of 8.7 nm and 9.9 nm, respectively [1]. besides, in hek293 cells stably expressing the hdp receptor, bw 245c could significantly increase camp production, with the ec50 value of 0.7 nm [2].
in vivo
in spontaneously hypertensive rats, intravenous bolus injection with bw 245c at the dose of 250 μg/kg could reduce the systolic and diastolic blood pressure by 23% and 34%, respectively [1].
target
dp1 receptor
IC 50
2.5 nm
references
[1] town h c, casalsstenzel j, schillinger e, et al. pharmacological and cardiovascular properties of a hydantoin derivative, bw 245 c, with high affinity and selectivity for pgd2 receptors[j]. prostaglandins, 1983, 25(1): 13-28.[2] boie y, sawyer n, slipetz d, et al. molecular cloning and characterization of the human prostanoid dp receptor[j]. journal of biological chemistry, 1995, 270(32): 18910-18916.[3] orchard m a, ritter j m, shepherd g l, et al. cardiovascular and platelet effects in man of bw 245c, a stable mimic of epoprostenol (pgi2)[j]. british journal of clinical pharmacology, 1983, 15(5): 509-511.
Check Digit Verification of cas no
The CAS Registry Mumber 72814-32-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,8,1 and 4 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 72814-32:
(7*7)+(6*2)+(5*8)+(4*1)+(3*4)+(2*3)+(1*2)=125
125 % 10 = 5
So 72814-32-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16+/m0/s1
72814-32-5Relevant articles and documents
Heterocyclic Prostaglandin Analogues. Part 3. The Relationship of Configuration to Biological Activity for Some Hydantoin Prostanglandin Analogues
Brockwell, Michael A.,Caldwell, A. Gordon,Whittaker, Norman,Begley, Michael J.
, p. 706 - 711 (2007/10/02)
The enantiomers of the two diastereomers of 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin have been synthesised.Potent inhibition of platelet aggregation in this series is associated with the configuration corresponding to that in the natural inhibitors, such as prostaglandins E1 and D2.
